摘要
度普利尤单抗治疗5例老年难治性大疱性类天疱疮(BP)患者。5例患者平均年龄为78.2岁,合并多种基础疾病。明确诊断后,给予其度普利尤单抗规律治疗3~5次,BP患者皮损得到控制,瘙痒明显缓解,定期随访中。度普利尤单抗是一种全人类IgG4单克隆抗体,通过与IL-4R和IL-13R-亚基的共同链结合,阻断IL-4/13信号传导途径,从而打断了BP发病的炎症通路,其还可通过对IL-4和IL-13的直接作用和对嗜酸性粒细胞的作用导致IL-31分泌减少,从而减少外周瘙痒感觉神经元的信号传递,因此可缓解老年BP的瘙痒问题。
We report five elderly patients with refractory bullous pemphigoid treated with dupuyuzumab.The average age was 78.2 years old,and they were complicated with various basic diseases.After a definite diagnosis,the skin lesions of bullous pemphigoid were controlled and the itching was obviously relieved after the regular treatment of duprizumab for 3-5 times,and the patients were followed up regularly.Duplex monoclonal antibody is a monoclonal antibody of human IgG4-4.By binding to the common chain of IL-4R and IL-13R-subunits,it blocks the IL-4/13 signaling pathway,thus interrupting the inflammatory pathway of BP.It can also reduce the secretion of IL-31 through its direct action on IL-4 and IL-13 and its action on eosinophils,thus reducing the signal transmission of peripheral itch sensory neurons.
作者
乌日嘎
贺伟
WU Riga;HE Wei(Department of Dermatology,Affiliated Hospital of Inner Mongolia Medical University,Hohhot 010050,China)
出处
《皮肤科学通报》
2024年第4期430-435,共6页
Dermatology Bulletin
基金
内蒙古自治区自然科学基金项目(2020MS08112)
内蒙古医科大学面上项目(YKD2021MS039)。
